Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | JAK3 | P52333 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | BTK | Q06187 | 3/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10283866 | 1.00 | ALDH1A1 (0.51) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL27451704 | 1.00 | ALDH1A1 (0.51) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL19353252 | 1.00 | ALDH1A1 (0.51) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL24348777 | 0.96 | ALDH1A1 (0.47) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL27451749 | 0.92 | JAK3 (0.43) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL18909618 | 0.92 | JAK3 (0.43) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL23547437 | 0.92 | JAK3 (0.43) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL18904853 | 0.92 | JAK3 (0.43) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL462693 | 0.85 | HPGD (0.46) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL27451677 | 0.85 | POLB (0.49) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426637-B1 | COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE | ANGEL PHARMACEUTICAL CO LTD (CN) | 2022-02-09 | — | — | EP | disclosed |
| EP-2529622-B1 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2018-01-17 | — | — | EP | disclosed |
| EP-2307025-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS LLC (US) | 2017-09-20 | — | — | EP | disclosed |
| WO-2017156495-A1 | COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE | CORVUS PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| US-20160361315-A1 | IBRUTINIB PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | NGUYEN MARK QUANG (US) | 2016-12-15 | — | — | US | disclosed |
| US-9394312-B1 | Ibrutinib prodrugs, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2016-07-19 | — | — | US | disclosed |
| US-8975266-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8957079-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8952015-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8759516-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8754091-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8748439-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748438-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8741908-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8735403-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735404-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8658653-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8158786-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20110257203-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | Phamarcyclics, Inc. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20100022561-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257203-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | ALDH1A1 4459/4885HPGD 2986/4885SMN1; SMN2 4262/4885 |
| US-20100022561-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | ALDH1A1 4459/4885HPGD 2986/4885SMN1; SMN2 4262/4885 |
| US-20160361315-A1 | IBRUTINIB PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | BTK, SYK, BCL9 | ALDH1A1 2864/4885HPGD 1921/4885SMN1; SMN2 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.